| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
| ISTURISA® | Novartis | Endogenous Cushing's syndrome/ Cushing's disease |
Approved in the USA, Europe and Switzerland Filed in Japan and other countries |
| CYSTADROPS® | Recordati | Corneal cysteine crystal deposits in patients with cystinosis | Approved in the EU and USA Development of new formulations in EU and in USA |
| REAGILA® | Gedeon Richter | Schizophrenia | Pediatric post-approval development plan |
| Methadone | Treatment of cancer-related pain in cases of resistance or intolerance to other opioids | Approved in France | |
| CARBAGLU® | (Recordati Rare Diseases) |
Hyperammonaemia due to NAGS deficiency and to the main organic acidemias | Approved in Canada and the USA for the treatment of organic acidemias |
| ARS-1 | ARS Pharmaceuticals | Emergency treatment of severe allergic reactions, including anaphylaxis | Filed in EU and pediatric development plan in progress |
| REC 0559 | Recordati/Mime Tech | Neurotrophic keratitis | Phase 2 in progress |
| REC 0545 | Recordati/AP-HP | Acute decompensation episodes in MSUD | Formulation development and retrospective study in France and Germany |